Published in Eur J Cancer on March 19, 2010
An overview of tissue and whole organ decellularization processes. Biomaterials (2011) 4.78
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 2.87
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev (2015) 2.51
Does tumour dormancy offer a therapeutic target? Nat Rev Cancer (2010) 2.19
The extracellular matrix modulates the hallmarks of cancer. EMBO Rep (2014) 1.88
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov (2012) 1.75
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis (2011) 1.68
Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology (2011) 1.65
The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov (2012) 1.45
The metastatic niche and stromal progression. Cancer Metastasis Rev (2012) 1.30
Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials (2012) 1.27
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res (2014) 1.16
Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem (2013) 1.15
Quantifying collagen structure in breast biopsies using second-harmonic generation imaging. Biomed Opt Express (2012) 1.14
Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol (2013) 1.14
Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduct (2011) 1.14
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol (2013) 1.02
MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. Nat Commun (2015) 1.01
Matrix rigidity regulates cancer cell growth by modulating cellular metabolism and protein synthesis. PLoS One (2012) 0.99
Vascular permeability and drug delivery in cancers. Front Oncol (2013) 0.99
The Nyhus-Wantz lectureship: etiology, herniosis, diverticulosis coli, and cancer. Hernia (2011) 0.97
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest (2013) 0.96
Intratumoral drug delivery with nanoparticulate carriers. Pharm Res (2011) 0.95
Molecular pathways: niches in metastatic dormancy. Clin Cancer Res (2014) 0.95
"A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies". BMC Cancer (2012) 0.92
Suppression of mitochondrial complex I influences cell metastatic properties. PLoS One (2013) 0.90
Prospective identification of glioblastoma cells generating dormant tumors. PLoS One (2012) 0.90
β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell (2011) 0.90
Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid (2011) 0.90
MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer (2011) 0.89
Dormancy in breast cancer. Breast Cancer (Dove Med Press) (2012) 0.89
Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine (2012) 0.89
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol (2013) 0.88
Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene (2015) 0.88
Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer (2013) 0.88
An in vitro system to study tumor dormancy and the switch to metastatic growth. J Vis Exp (2011) 0.88
The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression. Biomed Res Int (2013) 0.87
P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget (2014) 0.87
Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res (2011) 0.87
Snake venom disintegrins and cell migration. Toxins (Basel) (2010) 0.87
Molecular alterations associated with osteosarcoma development. Sarcoma (2012) 0.86
Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One (2010) 0.86
Alterations in Cell-Extracellular Matrix Interactions during Progression of Cancers. Int J Cell Biol (2012) 0.86
NF-κB p65 Subunit Is Modulated by Latent Transforming Growth Factor-β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. PLoS One (2015) 0.84
Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel) (2011) 0.84
Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. Mol Carcinog (2013) 0.83
Targeting dormant micrometastases: rationale, evidence to date and clinical implications. Ther Adv Med Oncol (2016) 0.83
A collapsin response mediator protein 2 isoform controls myosin II-mediated cell migration and matrix assembly by trapping ROCK II. Mol Cell Biol (2012) 0.82
Ion channels and anti-cancer immunity. Philos Trans R Soc Lond B Biol Sci (2014) 0.82
Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy". PLoS One (2013) 0.82
GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2. Cancer Res (2013) 0.82
ROCK inhibition activates MCF-7 cells. PLoS One (2014) 0.82
Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells. PLoS One (2014) 0.81
Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. Cancer Res (2015) 0.80
TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration. Br J Pharmacol (2014) 0.80
Whole-organ re-engineering: a regenerative medicine approach to digestive organ replacement. Surg Today (2012) 0.79
Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer. Mol Cancer Ther (2016) 0.79
Tumor matrix protein collagen XIα1 in cancer. Cancer Lett (2014) 0.79
Tumour progression and metastasis. Ecancermedicalscience (2016) 0.79
OASIS/CREB3L1 is induced by endoplasmic reticulum stress in human glioma cell lines and contributes to the unfolded protein response, extracellular matrix production and cell migration. PLoS One (2013) 0.79
Transcriptional profiling identifies genes induced by hepatocyte-derived extracellular matrix in metastatic human colorectal cancer cell lines. Clin Exp Metastasis (2012) 0.78
Interaction of tumour cells with their microenvironment: ion channels and cell adhesion molecules. A focus on pancreatic cancer. Philos Trans R Soc Lond B Biol Sci (2014) 0.78
Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. Int J Colorectal Dis (2012) 0.78
Binding of CD157 protein to fibronectin regulates cell adhesion and spreading. J Biol Chem (2014) 0.78
From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer Metastasis Rev (2016) 0.78
Epstein-Barr virus LMP1 induces focal adhesions and epithelial cell migration through effects on integrin-α5 and N-cadherin. Oncogenesis (2015) 0.77
TGFβ3-mediated induction of Periostin facilitates head and neck cancer growth and is associated with metastasis. Sci Rep (2016) 0.77
Synergistic therapeutic effect of cisplatin and phosphatidylinositol 3-kinase (PI3K) inhibitors in cancer growth and metastasis of Brca1 mutant tumors. J Biol Chem (2014) 0.77
Identification of novel drugs to target dormant micrometastases. BMC Cancer (2015) 0.77
Tissue-specific and SRSF1-dependent splicing of fibronectin, a matrix protein that controls host cell invasion. Mol Biol Cell (2013) 0.77
Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. J Cancer Res Clin Oncol (2012) 0.77
Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth. Oncotarget (2016) 0.77
Dynamic and influential interaction of cancer cells with normal epithelial cells in 3D culture. Cancer Cell Int (2014) 0.77
Cancer microenvironment and cancer vaccine. Cancer Microenviron (2012) 0.77
Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. Front Oncol (2015) 0.76
The Cohesive Metastasis Phenotype in Human Prostate Cancer. Biochim Biophys Acta (2016) 0.76
Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. Oncol Lett (2017) 0.75
Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis. Oncotarget (2016) 0.75
Role of EGFR expression levels in the regulation of integrin function by EGF. Mol Carcinog (2015) 0.75
Genipin crosslinking reduced the immunogenicity of xenogeneic decellularized porcine whole-liver matrices through regulation of immune cell proliferation and polarization. Sci Rep (2016) 0.75
Primary and metastatic tumor dormancy as a result of population heterogeneity. Biol Direct (2016) 0.75
Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clin Exp Metastasis (2014) 0.75
Extracellular matrix mediators of metastatic cell colonization characterized using scaffold mimics of the pre-metastatic niche. Acta Biomater (2016) 0.75
A gene expression-based comparison of cell adhesion to extracellular matrix and RGD-terminated monolayers. Biomaterials (2015) 0.75
Effects of Acellular Amniotic Membrane Matrix and Bone Marrow-Derived Mesenchymal Stem Cells in Improving Random Skin Flap Survival in Rats. Iran Red Crescent Med J (2016) 0.75
Breast Cancer Metastasis to the Axillary Lymph Nodes: Are Changes to the Lymph Node "Soil" Localized or Systemic? Breast Cancer (Auckl) (2017) 0.75
From competency to dormancy: a 3D model to study cancer cells and drug responsiveness. J Transl Med (2016) 0.75
Dual functions of NME1 in suppression of cell motility and enhancement of genomic stability in melanoma. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Advances in the Knowledge about Kidney Decellularization and Repopulation. Front Bioeng Biotechnol (2017) 0.75
Arp2/3 Complex Is Required for Macrophage Integrin Functions but Is Dispensable for FcR Phagocytosis and In Vivo Motility. Dev Cell (2017) 0.75
Engineering the pre-metastatic niche. Nat Biomed Eng (2017) 0.75
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Tensional homeostasis and the malignant phenotype. Cancer Cell (2005) 19.30
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol (1997) 10.61
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
A tense situation: forcing tumour progression. Nat Rev Cancer (2009) 7.80
Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med (1995) 7.37
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33
The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation (2002) 4.64
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell (2004) 4.34
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci U S A (1994) 3.09
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol (1999) 2.93
Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol (2003) 2.92
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
The organ microenvironment and cancer metastasis. Differentiation (2002) 2.81
Integrins: roles in cancer development and as treatment targets. Br J Cancer (2004) 2.76
Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 2.75
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res (2008) 2.63
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol (2005) 2.53
Three-dimensional context regulation of metastasis. Clin Exp Metastasis (2008) 2.49
Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res (2002) 2.36
Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell (2001) 2.21
Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem (2000) 2.19
Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat (2003) 2.14
Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst (1993) 2.14
Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res (2000) 2.06
Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem (2002) 1.99
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev (2006) 1.70
Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors. J Cell Biol (2003) 1.67
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res (2004) 1.57
Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol (2002) 1.57
Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle (2006) 1.54
Dormancy of solitary metastatic cells. Cell Cycle (2006) 1.53
Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res (2003) 1.50
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun (1999) 1.46
Extracellular matrix regulation of autophagy. Curr Opin Cell Biol (2008) 1.44
Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res (2006) 1.41
Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat (2006) 1.40
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A (2000) 1.37
Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucleic Acids Res (1995) 1.36
Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. EMBO J (2007) 1.32
Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer (2001) 1.31
Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol (2001) 1.30
High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.19
Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis (1999) 1.16
Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol (2002) 1.12
Role of tumor cell adhesion and migration in organ-specific metastasis formation. Onkologie (2004) 1.07
Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol (2005) 1.05
Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer (2010) 1.04
Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer (2002) 1.00
Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res (2009) 0.99
Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem (2009) 0.98
Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle (2006) 0.97
Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res (2009) 0.89
Histological factors associated with initial bone metastasis of invasive ductal carcinoma of the breast. Jpn J Cancer Res (1999) 0.86
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res (2008) 2.63
Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res (2002) 2.36
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res (2004) 2.33
In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med (2006) 2.32
Does tumour dormancy offer a therapeutic target? Nat Rev Cancer (2010) 2.19
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A (2002) 2.15
Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat (2003) 2.14
Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res (2010) 1.95
In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med (2006) 1.88
Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays (2002) 1.76
The biology of metastasis to a sanctuary site. Clin Cancer Res (2007) 1.72
Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res (2007) 1.70
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat (2008) 1.59
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem (2009) 1.59
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res (2004) 1.57
Dormancy of solitary metastatic cells. Cell Cycle (2006) 1.53
Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med (2010) 1.53
Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res (2006) 1.49
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer (2002) 1.49
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res (2007) 1.49
Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem (2007) 1.48
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 1.44
Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer (2007) 1.40
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res (2002) 1.39
Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Invest (2010) 1.32
A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr (2004) 1.32
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol (2006) 1.30
Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis (2006) 1.30
Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene (2003) 1.29
Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis (2007) 1.28
miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics (2011) 1.28
Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation. Bioinformatics (2010) 1.28
Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog (2005) 1.28
Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res (2008) 1.27
Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis (2006) 1.26
Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res (2003) 1.24
Tumour dormancy in breast cancer: an update. Breast Cancer Res (2007) 1.23
β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res (2011) 1.23
A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis (2005) 1.20
The role of apoptosis in tumor progression and metastasis. Curr Mol Med (2003) 1.20
Brain metastases of breast cancer. Breast Dis (2007) 1.20
Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis (2003) 1.18
Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res (2005) 1.18
Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene (2004) 1.18
Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res (2011) 1.18
Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal (2011) 1.17
Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry A (2005) 1.16
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res (2007) 1.14
In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol (2011) 1.14
Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res (2005) 1.13
Time-course characterization of the computed tomography contrast enhancement of an iodinated blood-pool contrast agent in mice using a volumetric flat-panel equipped computed tomography scanner. Invest Radiol (2006) 1.12
Effects of pooling mRNA in microarray class comparisons. Bioinformatics (2004) 1.10
Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol (2011) 1.09
Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One (2010) 1.09
Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest (2011) 1.07
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis (2003) 1.07
Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int J Cancer (2007) 1.05
Tumor dormancy and metastasis. Adv Cancer Res (2009) 1.04
Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection. BMC Med Genomics (2011) 1.04
Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer (2008) 1.04
Osteopontin and colon cancer progression. Clin Exp Metastasis (2003) 1.04
Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Res (2003) 1.03
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One (2011) 1.03
VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res (2009) 1.03
Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol (2009) 1.02
S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res (2012) 1.01
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol (2003) 1.00
Molecular mechanisms of metastasis. Cancer Metastasis Rev (2006) 1.00
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol (2003) 1.00
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene (2005) 1.00
Gene signatures of breast cancer progression and metastasis. Breast Cancer Res (2011) 0.99
Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res (2010) 0.98
Assessing cancer cell migration and metastatic growth in vivo in the chick embryo using fluorescence intravital imaging. Methods Mol Biol (2012) 0.97
Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer (2002) 0.97
Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal (2004) 0.97
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest (2013) 0.96
Osteopontin identified as colon cancer tumor progression marker. C R Biol (2004) 0.96
Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology (2005) 0.95
LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat (2013) 0.95
Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res (2002) 0.95
Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer (2005) 0.95
New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS (2008) 0.94
Radiation-induced lung injury after concurrent neoadjuvant chemoradiotherapy for locally advanced breast cancer. Acta Oncol (2014) 0.94
BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. Clin Exp Metastasis (2008) 0.94
Contrast-enhanced microcomputed tomography using intraperitoneal contrast injection for the assessment of tumor-burden in liver metastasis models. Invest Radiol (2008) 0.93
Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res (2008) 0.93
An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem Cell Biol (2011) 0.92
Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Res Treat (2003) 0.92
Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem (2006) 0.91
Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther (2005) 0.91
Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol (2005) 0.91
Human 21T breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression patterns. Lab Invest (2010) 0.90
In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T. J Magn Reson Imaging (2011) 0.90